ABN AMRO serves retail, private and commercial banking customers in the Netherlands and across the globe. Along with a comprehensive range of products and services, we offer in-depth financial expertise, extensive knowledge of numerous sectors and an international network supporting our customers’ domestic and international operations.  We aim to respond to the ever-changing market and, in doing so, to our customers’ ever-changing needs. Customers want a bank that acts in the context of today’s realities and is straightforward with them at all times; a bank that learns from its experiences and whose top priority is to provide the best possible service.

ABN AMRO Fund

Nazem and Company is a principal investment firm specializing in investments in seed, early, and late stages; follow on financings; and pre-IPO investments. It seeks to invest in all the stages of the company’s development. The firm also invests in stress and turnaround situations where it can lead reorganization efforts. It seeks to invest in companies in emerging, high-potential growth industries and mature markets. The firm prefers to invest in healthcare services, biotechnology and life sciences, electronics, information technology, telecommunications, and the Internet sectors. It seeks to invest in under-valued, profitable companies around the globe. The firm targets companies based in the United States. Nazem and Company was founded in 1976 and is headquartered in New York, New York with an additional office in Menlo Park, California.

Nazem and Company

Third Rock Ventures invests in transformational life science companies that show high growth potential and are well-positioned to make a difference in the marketplace. Third Rock Ventures believes in the companies we start and makes significant initial investments, which are frequently supplemented by strategic collaborations, to help our firms progress in life-changing medicines, technologies, and diagnostics.

Third Rock Ventures

Sanofi Ventures is the corporate venture capital arm of Sanofi. We have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health and data science solutions.

Sanofi Ventures

Easton Capital Investment Group manages approximately $200 million on behalf of a number of significant institutional investors in its three funds, Easton Capital Partners, L.P., Easton Hunt Capital Partners, L.P. and Easton Hunt New York LP. Easton makes investments ranging in size from $2 million to $7.5 million and has strategic co-investment relationships with many of its institutional investors which allow it to participate in larger initial and follow-on rounds of funding. Easton has offices in New York and Florida.

Easton Capital

TVM Capital is a global venture and growth capital firm that aims to finance select biopharmaceutical and medical device companies. TVM Capital was founded in 1983 and is based Munich, Bavaria.

TVM Capital

Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successful investments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed â‚¬400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.

Forbion Capital Partners

ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH has raised ten venture funds totaling over $3 billion and has invested in the venture capital rounds for more than 150 companies. ARCH investors include corporations, pension funds, endowment funds, financial institutions, and private investors.

ARCH Venture Partners

RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and board levels. The company invests in companies with promising technologies and products.

RA Capital Management

Deerfield Partners is a real estate brokerage firm focused exclusively on the sale of newly built Walgreens investment properties.

Deerfield Partners

ArmaVir Partners, formerly the Ramius Private Investments Group makes direct equity investments in operating companies and unique assets. It takes an active approach and makes control or significant minority investments in small-to-mid-sized operating companies. It also looks to make minority investments in select high growth private companies.  In 2018, Armavir Partners spun out of its former parent, Cowen Inc. ArmaVir Partners has over $300 million in assets under management. ArmaVir Partners is actively seeking new investment opportunities in North America and Western Europe. Typically it looks to invest $10-100+ million. The firm is generalists, with significant experience in telecommunications, consumer products, industrials, financial services, and renewable energy.

ArmaVir Partners

Bluebird Bio

TC BioPharm develops safer, cheaper, consistent, and durable CAR-T drugs for hematological and solid tumors. TC BioPharm’s mission is to develop and commercialize innovative cell-based products to treat disease, improving patient health and quality of life. TC BioPharm is a clinical development company with a cell-based product pipeline capable of treating a variety of disorders, including cancer and severe viral infections. TCB is currently conducting Phase II/III clinical studies of its lead product, ImmuniCell, in renal cell cancinoma, non-small cell lung cancer and melanoma patients.

bluebird bio is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.

Bluebird Bio is a gene therapy provider that is developing therapeutics to treat conditions associated with cell disease, genetic diseases, and neurological diseases. Specifically, the company focuses on developing therapies for thalassemia, cerebral adrenoleukodystrophy (CALD), and sickle cell disease. Bluebird develops lentiviral vectors (LVVs) designed to address the causes of specific diseases and are delivered as single-dose treatments to patients. The company is listed on the Nasdaq and is publicly traded under the ticker symbol BLUE, and claims to have the largest ex-vivo gene therapy data set in the world. 2seventy bio was spun out of Bluebird Bio in November 2021 and functions as an oncology cell therapy company.

Novel therapies to reboot cells and organs

Cell & Gene Therapy

Bluebird Bio is laying off 25 percent of its workers to cut costs

Bristol-Myers Squibb

bluebird bio and Bristol Myers Squibb amend agreement to streamline commercialization of idecabtagene vicleucel (ide-cel; bb2121) in the U.S., focusing efforts on bringing the BCMA-directed CAR T cell therapy to patients.

Bluebird Bio is a gene therapy provider that is developing therapeutics to treat conditions associated with cell disease, genetic diseases, and neurological diseases. Specifically, the company focuses on developing therapies for thalassemia, cerebral adrenoleukodystrophy (CALD), and sickle cell disease. Bluebird develops lentiviral vectors (LVVs) designed to address the causes of specific diseases and are delivered as single-dose treatments to patients. The company is listed on the Nasdaq and is publicly traded under the ticker symbol BLUE, and claims to have the largest ex-vivo gene therapy data set in the world. 2seventy bio was spun out of Bluebird Bio in November 2021 and functions as an oncology cell therapy company.The company has three commercialized therapeutics: SKYSONA for the treatment of CALD in patients less than 18 years, ZYNTEGLO for the treatment of thalassemia in adults, and LYFGENIA for the treatment of sickle cell disease. As of April 2024, the company had two candidates for the treatment of sickle cell disease, SCD (HGB-210) and SCD (HGB-206), which were in Phase III clinical trials and Phase I/II clinical trials, respectively. Key customers and partnershipsBluebird Bio partnered with biotechnology company Magenta Therapeutics in December 2020 to create a research collaboration to carry out a Phase II clinical proof-of-concept study for Magenta’s novel mobilization regimen, MGTA-145, for mobilization and collection of stem cells in patients with sickle cell disease (SCD).Bluebird Bio also partnered with biotechnology company National Resilience, Inc in July 2021 to accelerate research, development, and delivery of cell therapies. Through the partnership, National Resilience acquired Bluebird Bio’s Research Triangle manufacturing facility in North Carolina, along with more than 100 technical staff. Resilience was expected to continue to support vector supply for both Bluebird Bio and 2seventy bio.

<div>
 
 Tenaya Therapeutics is a developer of therapeutics for heart disease. The company develops its therapeutics using precision medicine, gene therapy, and cellular regeneration. Tenaya produces therapeutics that also use proprietary in-vivo and in-vitro models. Additionally, the company has developed in-house adeno-associated virus (AAV) capsid engineering capabilities and has screened over one billion variants from more than 30 diverse, proprietary AAV libraries. The company is publicly listed on the Nasdaq and trades under the ticker symbol TNYA.&nbsp;&nbsp;
 
 
 In October 2023 Tenaya Therapeutics (Tenaya) received FDA clearance for the company&rsquo;s investigational new drug application (TN-401) to initiate clinical testing. TN-401 is Tenaya&rsquo;s adeno-associated virus serotype 9-based investigational gene therapy drug candidate for the treatment of arrhythmogenic right ventricular cardiomyopathy caused by mutations in the plakophilin-2 gene. 
 
 
 As of May 2024, the company&rsquo;s clinical pipeline included two candidates in Phase I clinical trials, a gene therapeutic for the treatment of Hypertrophic Cardiomyopathy, and a small molecule inhibitor for the treatment of heart failure with preserved ejection fraction. Additionally, Tenaya had one gene therapy candidate and two genetic medicine candidates in preclinical testing phases, along with five genetic medicine candidates in the discovery stage. 
 
 
 
</div>

Tenaya Therapeutics

<div>
 
 Sarepta Therapeutics is a gene therapy provider for conditions such as Duchenne Muscular Dystrophy (DMD), Limb-Girdle Muscular Dystrophy 
 (LGMD), and Charcot-Marie-Tooth Disease. The company&rsquo;s therapeutics incorporate technology related to gene therapy, RNA technologies, and gene editing. The company leverages a proprietary phosphorodiamidate morpholino oligomer (PMO) platform for the development of its RNA-based therapeutics. As of August 2023, the company had four FDA-approved treatments for DMD: ELEVIDYS, EXONDYS 51, VYONDYS 53, and AMONDYS 45. Sarepta Therapeutics is also listed on the Nasdaq, trading under the symbol SRPT.&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 As of May 2024, the company had several RNA, gene, and gene editing therapeutics in various clinical stages. Sarepta had two RNA therapeutics, both for the treatment of DMD, one in clinical testing, and the other in pre-clinical testing. Additionally, the company had six gene therapeutics, one for the treatment of DMD (both in clinical testing), four for the treatment of LGMD (three in clinical testing, one in preclinical testing) and one for multiple targets (in preclinical testing). Also, Sarepta had two gene editing-based therapeutics in development for the treatment of DMD, both in preclinical testing phases. 
 
 
 
 
 Key customers and partnerships
 
 
 
 
 Over the years since its founding, Sarepta has partnered with several industry and academic partners. The list includes Dyno Therapeutics, Genethon, Genevant Sciences, Hansa Biopharma, Roche, Columbia University, Harvard University, Translational Laboratory of Murdoch University, University of Florida College of Medicine, The Abigail Wexner Research Institute at Nationwide Children&rsquo;s Hospital, University of Massachusetts Medical School, and the University of Western Australia.&nbsp;&nbsp;
 
 
 
 
 In October 2021, Sarepta and healthcare giant Roche announced they would collaborate on carrying out a clinical study of Sarepta&rsquo;s therapeutic candidate SRP-9001 for the treatment of DMD.&nbsp;
 
 
 
 
 Sarepta and pharmaceutical company Catalent announced that in January 2023, the companies were signing a commercial supply agreement. Through the agreement,&nbsp; Catalent would manufacture Sarepta&rsquo;s gene therapeutic for the treatment of DMD; delandistrogene moxeparvovec (SRP-9001).
 
 
 
</div>

Sarepta Therapeutics

<div>
 
 Mesoblast is a cell therapy manufacturer that provides therapeutics for oncology, cardiovascular, orthopedic, hematology, immunity, and inflammation-related conditions. The company is listed on the Australian Stock Exchange and trades under the ticker symbol &ldquo;MSB.&rdquo; Mesoblast develops therapeutics using its proprietary mesenchymal lineage cell technology platform, which is used to produce cryopreserved, off-the-shelf, and cellular-based solutions. The company also incorporates 3D bioreactor technology and automation into its production process to produce higher yields.&nbsp;
 
 
 
 
 As of May 2024, the company had five candidates that are in various stages of clinical testing. Mesoblast&rsquo;s steroid-refractory candidate for Acute Graft Versus Host Disease is currently in late-stage Phase III clinical testing and is the closest candidate to commercialization. The company&rsquo;s drug candidates for acute respiratory distress syndrome, chronic low back pain, and chronic heart failure and reduced ejection fraction are also in Phase III clinical testing while its candidate for inflammatory bowel disease is in Phase II of clinical testing.&nbsp;
 
 
 
 
 Key customers and partnerships
 
 
 
 
 The company has secured several agreements with international companies with regard to development and commercialization of Mesoblast&rsquo;s candidates, including Gr&uuml;nenthal GmBH, JCR Pharmaceuticals, Tasly Pharmaceutical Group, TiGenix NV, and the Lonza Group.&nbsp;
 
 
 
 
 Additionally, in April 2020, Mesoblast partnered with The US NIH&rsquo;s National Heart, Lung, and Blood Institute to conduct testing of its allogeneic mesenchymal stem cell (MSC) product candidate, &ldquo;remestemcel-L.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;
 
 
 
 
 
</div>

Mesoblast

<div>
 
 Ocugen is a gene therapy manufacturer that develops vaccine, cell, and gene-based therapeutics for infectious, eye, and orthopedic diseases. Its cell therapy includes a three dimensional tissue-engineered cartilage disk through the growth of chondrocytes &ndash; the cells responsible for maintaining cartilage health. Its gene therapy solution consists of creating a copy of the patient&rsquo;s gene in order to replace mutated/damaged genes. The company is publicly listed on the Nasdaq, and trades under the symbol &lsquo;OCGN&rsquo;.&nbsp;
 
 
 As of May 2024, the company had five therapeutic solutions being clinically tested. The company was developing four gene therapies for the treatment of retinitis pigmentosa, Leber congenital amaurosis, geographic atrophy, and orphan disease. Its treatment candidate for retinitis pigmentosa was in Phase III of clinical study, while its other gene therapies were in Phase I/II. 
 Ocugen was also developing a biological material, in the IND stage, for diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration. The company's cell therapy for the treatment of articular cartilage defects in the knee was in Phase III of clinical study. Finally, the company was also developing three vaccines, all in IND stages, for prevention of diseases caused by the flu, Covid-19, and a combination of the flu and Covid-19.
 
 
 Key customers and partnerships
 
 
 Ocugen partnered with biopharmaceutical manufacturer Jubilant HollisterStier of Spokane in June 2021 to manufacture its Covid-19 therapeutic COVAXIN. Through the partnership, Jubilant would be the potential commercial manufacturer of Ocugen&rsquo;s vaccine for the US and Canadian markets.
 
 
 
 
 
</div>

Ocugen

<div>
 
 MeiraGTx is a developer of gene therapies that aim to treat ocular diseases and problems, neurodegenerative disorders, and salivary gland and autoimmune disorders. MeriaGTx is also developing riboswitch-inducible expression programs for the treatment of inherited obesity and Wilson disease, along with producing small-molecule riboswitch inducers. The company is listed on the Nasdaq and trades under the symbol MGTX.&nbsp;&nbsp;
 
 
 As of May 2024, the company had four gene-based therapeutic candidates in Phase II of their clinical trials for the treatment of (1) xerostomia, Parkinson's Disease, and RPE65-Associated retinal dystrophy and (2) achromatopsia. The company also had one therapeutic being developed to treat Sjogren&rsquo;s Syndrome that was in Phase I/II of its clinical trials. Additionally, MeiraGTx had seven other therapeutics in discovery/preclinical stages. The company was also developing a therapeutic for X-linked retinitis pigmentosa in collaboration with Janssen, which was in Phase III of clinical trials. 
 
 
 Key customers and partnerships
 
 
 MeiraGTx partnered with the International Institute of Risk and Safety Management (IIRSM) in November 2022 to influence risk agendas, raise awareness, the standards of risk, and safety management across the industry.&nbsp;
 
 
 Funding and financials
 
 
 Meira last raised funds in October 2023, when the company secured a strategic investment of USD 30 million from Sanofi. As part of the transaction, Sanofi was granted the right of first negotiation for MeiraGTx's gene regulation technology in certain targets.&nbsp;
 
 
 
</div>

MeiraGTx

Companies producing cells, genes, tissues, and biomaterials such as exosomes and extracellular matrix for drug developers and pharmaceutical companies developing regenerative medicine

Chimeric antigen receptor T-cell (CAR-T) therapy involves genetically engineering T cells to target and kill cancer cells

Companies conducting R&D on therapies that modify or introduce new genes into the body to treat diseases

Includes therapies that use cells (other than CAR-T and stem cells) such as Adipose-Derived Regenerative Cells (ADRCs), cardiosphere-derived cells, and gamma delta T cells (GDT cells)

Stem cell therapy involves using stem cells usually extracted from the bone marrow and umbilical cord blood to repair a variety of diseases

Startups in the hub consider individual patient profiles, involving variability in genes, environment, and lifestyle

Genomics helps understand the genetic information stored in the DNA to develop targeted treatments

<div>
 Bluebird Bio, a gene therapy company, has obtained a five-year loan of USD 175 million from Hercules Capital. The loan comprises an immediate disbursement of USD 75 million at the closing of the deal, two available tranches of USD 25 million each based on commercial milestones, and a possible fourth tranche of USD 50 million at Hercules' decision.
 The company plans to use the loan to fund the commercial launches of their three FDA-approved gene therapies: LYFGENIA, ZYNTEGLO, and SKYSONA. This financing is foreseen to extend the company's cash runway until Q1 2026.&nbsp;
 
</div>

Bluebird Bio

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless